
    
      Primary Endpoints:

        -  Acute gastrointestinal (GI) and genitourinary (GU) Common Terminology Criteria for
           Adverse Events (CTCAE) v3.0 toxicities

      Secondary Endpoints:

        -  Late GI and GU Radiation Therapy Oncology Group (RTOG) toxicities

        -  Biochemical disease-free survival

        -  Biopsy positive rate at 3 years

        -  Quality of life using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire

        -  Develop a biobank of DNA and serum extracted from blood and urine to analyze and develop
           new biomarkers for prostate cancer progression or susceptibility to severe toxicity
    
  